^
Association details:
| Biomarker: | FGFR3 amplification + FGFR4 amplification + FLT4 amplification |
|---|---|
| Cancer: | Ewing Sarcoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma
Excerpt:
...we did not see any responses to the combination of pazopanib and trametinib (GSK1120212) in patients with Ewing sarcoma. Next-generation sequencing of the molecular profile of one of the patients with Ewing sarcoma was compared with a previous patient who had a response to pazopanib in our clinic, and we found that three genes (FGFR3, FGFR4, and FLT4) were amplified only in the responder (Table 3)....Amplification of three genes in patient with Ewing sarcoma from a previous study who responded to treatment with pazopanib, compared with a patient with Ewing sarcoma in the current study who did not respond to combination treatment.
DOI:
10.1158/1078-0432.CCR-17-0272
